![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
scif_yarПо метро крутят рекламу - сдавайте плазму, поможите больным.
Ну чо
Our search identified and was informed by evidence from eleven RCTs and a large (n=20,000), single-arm registry study [112-116, 118-121, 124-126], as they provided the best available evidence for the outcomes of mortality, need for mechanical ventilation, serious adverse events, and adverse events. Ten of those RCTs reported on convalescent plasma transfusions for patients hospitalized with COVID-19 (Table 10) [112-115, 118-121, 124, 125] and one RCT reported on receipt of convalescent plasma by ambulatory persons with mild COVID-19 disease (Table 11) [116].
Ten trials randomized 13,026 patients hospitalized with COVID-19 to receive a transfusion with COVID-19 convalescent plasma [112-115, 118-121, 124, 125]. Several trials were open-label and/or had concerns with risk of bias due to lack of adjustment for critical confounders or potential for residual confounding (Table s14a). Timing of receipt of COVID-19 convalescent plasma during the clinical course of the patients’ illness varied across studies (Table s13). One trial reported on 160 persons who received high-titer convalescent plasma less than 72 hours after the onset of symptoms of COVID-19 (mean age: 77.2 years; standard deviation: ±8.6 years) [116]. In addition, Joyner 2020 reported on safety outcomes of over 20,000 patients enrolled in the same FDA Expanded Access Program for COVID-19 convalescent plasma study.
https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
Ну чо
Our search identified and was informed by evidence from eleven RCTs and a large (n=20,000), single-arm registry study [112-116, 118-121, 124-126], as they provided the best available evidence for the outcomes of mortality, need for mechanical ventilation, serious adverse events, and adverse events. Ten of those RCTs reported on convalescent plasma transfusions for patients hospitalized with COVID-19 (Table 10) [112-115, 118-121, 124, 125] and one RCT reported on receipt of convalescent plasma by ambulatory persons with mild COVID-19 disease (Table 11) [116].
Ten trials randomized 13,026 patients hospitalized with COVID-19 to receive a transfusion with COVID-19 convalescent plasma [112-115, 118-121, 124, 125]. Several trials were open-label and/or had concerns with risk of bias due to lack of adjustment for critical confounders or potential for residual confounding (Table s14a). Timing of receipt of COVID-19 convalescent plasma during the clinical course of the patients’ illness varied across studies (Table s13). One trial reported on 160 persons who received high-titer convalescent plasma less than 72 hours after the onset of symptoms of COVID-19 (mean age: 77.2 years; standard deviation: ±8.6 years) [116]. In addition, Joyner 2020 reported on safety outcomes of over 20,000 patients enrolled in the same FDA Expanded Access Program for COVID-19 convalescent plasma study.
https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
